Table 1: Randomized, Comparative Trials of Oral Therapy for Clostridium difficile Diarrhea

 

Table 2.  Empirical Treatment Strategies for Patients with Multiple

Recurrences of C. difficile Diarrhea

Strategy

Repeated courses of antimicrobial agents (metronidazole, vancomycin, nitazoxanide, rifaximin)

Tapering doses of antimicrobial agents (vancomycin, rifaximin)

Biotherapy

            Ingestion of bacteria that normally inhabit the bowel (probiotics)

            Ingestion of non-toxigenic C. difficile

            Infusion of normal feces (fecal transplantation)

Monoclonal antibody to C. difficile toxins

Intravenous immunoglobulin

 

Table 3. Potential Future Treatment Options

 

Product

Type

Stage of Development

Company

 

C. difficile vaccine

 

Vaccine

 

Phase I

 

Acambis

Monoclonal Antibody

Antibody

Phase III

Merck

Nitazoxanide

Antibiotic

Phase III

Romark

Ramoplanin

Antibiotic

Phase III

Oscient

Rifaximin

Antibiotic

Phase III

Salix

 

Figure 1: Three Hit Disease